
A buoyant stock market, cheaper pump prices, and the housing revival are trumping the worrisome negatives

Cheaper Asian imports and economic disaster in Europe has made U.S. manufacturing soft

Sounds like Watergate was a lot of fun. No wonder Washington's old hands can't help but reminisce

Almost 80 percent of the U.S. military's mobile devices are BlackBerry products, but now that will probably change

A government crackdown on foreign investment has sent speculators fleeing, but one man is more bullish than ever

Quit-smoking apps get hot in a $1 billion market

On a new reality TV show, first prize is a fast-food outlet. Winners, beware

For some, Joel Peterson says, online courses or specialized one-year programs may be better choices than the MBA

Bitcoin crashed last month. That hasn't stopped venture capital firms from investing in Bitcoin companies
Age: 53
Chairman and Managing Director, Sun Pharmaceuticals
Dilip Shanghvi's low-key management style has turned Sun Pharma, maker of generic and branded drugs, into one of the most profitable pharma companies in India. Sun's priorities include cardiology, neurology, and psychiatry drugs. Shanghvi pursued M&As at home and overseas at a time when Indian companies rarely went shopping. Having waged a two-year legal battle, he hopes to score a big win soon with Sun gaining control over generics drugmaker Taro Pharmaceuticals of Israel.